Latest news with #NFL-101
Business Wire
3 days ago
- Health
- Business Wire
NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces the launch of a scientific collaboration with McLean Hospital, a member of the Mass General Brigham healthcare system in Boston, USA. This new collaboration aims to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. This collaboration follows studies conducted with the Georges Pompidou European Hospital (HEGP) and the French Alternative Energies and Atomic Energy Commission (CEA) which highlighted NFL-101's ability to restore normal brain activity in regions associated with tobacco craving, particularly the thalamus, during withdrawal. This restoration proved to be both specific and sustained. These results suggest the existence of a unique mechanism of action involving an interaction between the immune system and the central nervous system, distinct from existing treatments that directly target nicotinic receptors. The studies conducted by McLean Hospital will explore in greater detail the links between this brain activity restoration and established biomarkers of tobacco addiction, with the objective of further characterizing NFL-101's pharmacological profile. Three laboratories at McLean Hospital, will be involved in this project: the Integrative Neurochemistry Laboratory, the Behavioral Neuroimaging Laboratory, and the Behavioral Psychopharmacology Research Laboratory. This collaboration represents a strategic milestone aligned with the upcoming Phase III trial. It also supports NFL Biosciences' international expansion, particularly in the United States, through collaborations with world-renowned experts in addiction science. The results will further strengthen NFL Biosciences' regulatory submission. Launched at a pivotal time, this initiative contributes to the momentum of ongoing discussions with potential industrial partners. Under this agreement, NFL Biosciences will retain exclusive intellectual property rights, including any potential patent applications resulting from the work conducted jointly with McLean Hospital. The results of this collaboration may lead to co-authored publications in peer-reviewed scientific journals and presentations at international conferences by the McLean Hospital research teams involved in the project. These studies will further enhance the scientific visibility of the NFL-101 program. Professor Scott Lukas, Director of the McLean Imaging Center and the Behavioral Psychopharmacology Research Laboratory at McLean Hospital (USA), stated: 'With botanical drugs, efficacy often relies on the full extract, making it challenging to identify a precise mechanism of action. Too often, we develop molecules with a clearly defined mechanism, yet based on an incomplete understanding of addiction pathways, which frequently leads to setbacks in clinical trials. Here, it's the opposite: we already have demonstrated clinical effects, and the mechanism remains to be further explored. The next stage is to better understand the mechanism of action, which could strengthen the scientific rationale for the treatment and open the door to additional therapeutic insights, including potential individualized approaches.' Bruno Lafont, Chief Executive Officer and co-founder of NFL Biosciences commented: 'We are delighted to collaborate with McLean Hospital on this research project. Following the teams at the CEA and the Georges Pompidou European Hospital, this new collaboration further strengthens our program with complementary world-class expertise, particularly in addiction science and botanical drug pharmacology. It represents a key milestone in our commitment to deepen the understanding of NFL-101's mechanism of action and enhance its scientific and industrial appeal.' About McLean Hospital McLean Hospital has a continuous commitment to put people first in patient care, innovation and discovery, and shared knowledge related to mental health. It is consistently named the #1 freestanding psychiatric hospital in the United States by U.S. News & World Report and is #2 in America for psychiatric care in 2024-25. McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of Mass General Brigham. To stay up to date on McLean, follow us on Facebook, YouTube, and LinkedIn. About NFL Biosciences: NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on
Business Wire
22-07-2025
- Business
- Business Wire
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners. NFL Biosciences obtained a €600,000 'Innovation Advance' repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate. This €1.2 million adds to the €3.0 million raised in the oversubscribed capital increase at the end of May 2025. The company also expects to secure additional non-dilutive funding and plans to benefit each year from the reimbursement of a portion of its R&D expenses through the Research Tax Credit. These funds are allocated to the continued development of NFL-101, its proprietary drug indicated for smoking cessation. The company is currently engaged in scientific advice procedures with European regulatory authorities and the FDA. The feedback expected at the end of the summer will enable the company to confirm its development strategy, notably in relation to manufacturing, preclinical and clinical aspects. 'We would like to sincerely thank Bpifrance for its support, as well as our banking partners Société Générale and Banque Populaire du Sud. We have recently secured €4.2 million to support our development, and we are confidently approaching the launch of Phase 3. We are also continuing to seek additional non-dilutive funding and remain focused on rigorously managing our structural costs,' commented Bruno Lafont, Chief Executive Officer of NFL Biosciences. About NFL Biosciences: NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on
